These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 955267)

  • 1. Preparation and characterization of live recombinant influenza vaccine.
    Stealey VM; McCahon D; Freestone DS
    Dev Biol Stand; 1976; 33():191-6. PubMed ID: 955267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical trial of WRL 105 strain live attenuated influenza vaccine comparing four methods of intranasal vaccination.
    White WG; Freestone DS; Bowker CH; Barnes GM; Letley E; Ferris RD
    Dev Biol Stand; 1976; 33():202-6. PubMed ID: 782970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural challenge of subjects vaccinated with WRL 105 strain live influenza vaccine in a residential community.
    Morris CA; Freestone DS; Stealey VM
    Dev Biol Stand; 1976; 33():197-201. PubMed ID: 782969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials with intranasally administered WRL 105 strain live influenza vaccine in volunteers.
    Freestone DS
    Dev Biol Stand; 1976; 33():207-12. PubMed ID: 782971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of ferrets to infection with a live attenuated influenza virus and to subsequent heterologous challenge.
    Delem A
    Dev Biol Stand; 1976; 33():226-33. PubMed ID: 955269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of resistance to influenza virus infection in animal models.
    Potter CW; McLaren C; Jennings R
    Dev Biol Stand; 1975; 28():307-18. PubMed ID: 1126574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of A/Victoria/3/75 recombinants: development of an attenuated strain RIT 4050.
    Lobmann M; Delem A; Jovanović D
    Dev Biol Stand; 1977 Jun 1-3; 39():43-6. PubMed ID: 604127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HI antibody response in volunteers vaccinated with live influenza A/New Jersey/76 vaccine.
    Ikić D; Smerdel S; Manhalter T; Pasini N; Delimar N
    Dev Biol Stand; 1977 Jun 1-3; 39():67-71. PubMed ID: 342319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
    Schmidt S; Süss J; Oehring H; Schmidt J
    Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Mehta HB; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden FG; Bernstein DI; Kotloff K; King J; Piedra PA; Block SL; Yan L; Wolff M
    J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live tissue culture influenza vaccine for oral administration. I. Specific immune response to monovaccine A (H3N2) in volunteers.
    Alekseeva AK; Andzhaparidze OG; Gracheva EN; Sidorova LA; Melnikova SK
    Acta Virol; 1979 Jan; 23(1):59-66. PubMed ID: 35960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Criteria in the evaluation of live intranasal influenza virus vaccines.
    Zygraich N
    Dev Biol Stand; 1976; 33():141-50. PubMed ID: 782962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of an attenuated influenza A (H3N2) strain "KO-1" by recombination with A/Okuda/57 (H2N2) followed by selection of inhibitor-resistant virus.
    Yamada A; Okuno Y; Takahashi M; Nakajima K
    Biken J; 1980 Mar; 23(1):25-32. PubMed ID: 7437002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WRL 105 strain live attenuated influenza vaccine; comparison of one and two dose schedules.
    Evans AE; Letley E; Ferris RD; Freestone DS
    J Hyg (Lond); 1976 Dec; 77(3):327-32. PubMed ID: 1069813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses to vaccination with WRL 105 strain live influenza vaccine in previously vaccinated and unvaccinated volunteers.
    Evans AE; Simmons RL; Ferris RD; Hasell SK; Letley E; Freestone DS
    J Hyg (Lond); 1979 Jun; 82(3):489-95. PubMed ID: 448065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of nasal application of inactivated influenza vaccine.
    Fukumi H
    Dev Biol Stand; 1976; 33():155-61. PubMed ID: 782963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to combined live influenza virus vaccines administered intranasally.
    Peetermans J; Lamy F; Delem A
    Dev Biol Stand; 1975; 28():340-6. PubMed ID: 1126578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant WRL 105 strain live attenuated influenza vaccine. Immunogenicity, reactivity, and transmissibility.
    Morris CA; Freestone DS; Stealey VM; Oliver PR
    Lancet; 1975 Aug; 2(7927):196-9. PubMed ID: 51958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.